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Aim: To  quantify  gender, age-group  and quantity  of methadone prescribed  as  risk factors  for  drugs-related
deaths  (DRDs), and  for  methadone-specific  DRDs,  in Scotland’s  methadone-prescription  clients.
Design:  Linkage to death-records  for  Scotland’s  methadone-clients with one  or  more  Community  Health
Index  (CHI)-identified  methadone  prescriptions  during July 2009 to June 2013.
Setting: Scotland’s  Prescribing Information  System and  National  Records  of Scotland.
Measurements:  Covariates  defined  at  first CHI-identified  methadone  prescription,  and  person-years at-
risk (pys)  thereafter until  the  earlier of death-date  or  31 December  2013.  Methadone-specific  DRDs
were  defined as:  methadone implicated  but neither heroin  nor  buprenorphine.  Hazard  ratios  (HRs)  were
assessed using proportional  hazards  regression.
Findings: Scotland’s  CHI-identified  methadone-prescription  cohort comprised  33,128  clients,  121,254
pys,  1,171  non-DRDs and  760 DRDs  (6.3 per  1,000  pys), of which  362  were methadone-specific.  Irrespec-
tive  of gender,  methadone-specific  DRD-rate,  per 1,000  pys,  was  higher in  the  35+ age-group  (4.2;  95%
CI:  3.6–4.7)  than  for  younger clients  (1.9; 95% CI: 1.5–2.2). For methadone-specific  DRDs,  age-related HRs
(e.g.,  2.9 at  45+ years; 95% CI:  2.1–3.9) were  steeper  than  for all DRDs  (1.9;  95%  CI: 1.5–2.4); there  was no
hazard-reduction  for  females;  no  gender  by age-group  interaction;  and,  unlike  for  all DRDs,  the  highest
quintile  for  quantity  of  prescribed methadone at  cohort-entry  (>1960  mg)  was  associated  with  increased
HR  (1.8;  95%  CI: 1.3–2.5).
Conclusion: Higher  methadone-specific  DRD rates in older clients,  irrespective  of gender, call  for  bet-
ter  understanding of methadone’s  pharmaco-dynamics  in older,  opioid-dependent  clients, many  with
progressive  physical or  mental  ill-health.
© 2016 The Authors.  Published  by  Elsevier Ireland  Ltd.  This  is  an open access article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Despite other options (buprenorphine, morphine, heroin)
methadone, prescribed as a  1 mg/1 ml  solution, is the major con-
tributor to opioid substitution therapy (OST) globally and accounts
for the vast majority of Scotland’s OST over the past 30 years
(World Health Organization, 2009; Department of Health et al.,
1999, 2007; National Institute for Health and Clinical Excellence,
2007; Information Services Division and Scotland, 2015). With a
∗ Corresponding author at: MRC Biostatistics Unit, Cambridge, CB2 0SR, United
Kingdom.
E-mail  address: sheila.bird@mrc-bsu.cam.ac.uk (S.M. Bird).
population of 5.2 million, including 60,000 problem drug users,
Scotland dispensed around 600,000 L  of methadone per annum
from 2009 to  2013. The Scottish Drug Strategy Delivery Commission
(2013),  tasked by Scottish Ministers to conduct an independent
review of Scotland’s OST, endorsed the professional standards
(including supervision) by which opioid dependency was  man-
aged in  Scotland and also the value of methadone as a  treatment
which halves clients’ risks of drugs-related death (DRD) and
reduces blood-borne viruses and criminality (Strang et al., 2010;
Degenhardt et al., 2011; White et al., 2015; Pierce et al., 2016,
2015b).
Over the past decade, different study methods in  different juris-
dictions have persuaded the addiction community that there is
a  strong empirical interaction between gender and age-group in
http://dx.doi.org/10.1016/j.drugalcdep.2016.08.627
0376-8716/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC  BY license (http://creativecommons.org/licenses/by/4.0/).
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DRD-rates, whereby female opioid users’ experience a much lower
DRD-rate than their male counterparts at younger ages but, pro-
gressively, this advantage weakens beyond 35 years of age. We
conjectured that the prescribing of methadone could be implicated
in this gender by  age-group interaction.
Methadone prescribing was under scrutiny in  Scotland because
DRDs in which methadone was implicated were increasing, even
allowing for the quantity prescribed (as proposed by  Strang et al.,
2010) and because only a minimum estimate for Scotland’s num-
ber of methadone-clients could be given (The Scottish Government,
2008; HM Government, 2010; Ferguson, 2012; Scottish Public
Health Observatory, 2015): latterly, those identifiable by their Com-
munity Health Index (CHI) number (Ellison, 2015). A CHI-number
is uniquely assigned to  patients in Scotland’s National Health
Service (NHS) and used as a  basis for efficient, trusted record-
linkage (Pavis and Morris, 2015). However, the availability of the
CHI-number on methadone prescriptions varies by  prescription-
source (Dimitropoulou et al., 2016; Alvarez-Madrazo et al., 2016),
being higher for prescriptions issued by general practitioners (GPs)
than for other-source prescriptions which are used by commu-
nity drug services. Using CHI-numbers and plausible assumptions,
Dimitropoulou et al. (2016) developed an upper bound for Scot-
land’s number of methadone-clients: from July 2012 to June 2013
(hereafter 2012/13), 16,900 to 19,600 were managed by Scotland’s
GPs but the totality of methadone-clients was 25,100 to 36,500.
Greater precision was possible for GP-clients because, by 2012/13,
the majority (86%) of methadone prescriptions by GPs had the
client’s CHI-number in  contrast to 47% for other-source prescrip-
tions.
Questions were raised, and continue to be  in the media
(Ferguson, 2012; Ellison, 2015), about the persistence of Scotland’s
methadone clients across prescription-years, which was substan-
tial during 2009/10 to  2012/13 (see Supplementary material.1).
People on longer-term methadone maintenance are, of course,
ageing and their DRD-rate rises accordingly (Pierce et al., 2016;
Merrall et al., 2012; Pierce et al., 2015a; King et al., 2013, 2014;
Cousins et al., 2011; Cornish et al., 2010; Bird et al., 2010).
We hypothesised that possible reasons for OST clients’ increas-
ing  DRD-rate with age included the methadone prescribed to
older clients (Dimitropoulou et al., 2016), as directly implicated or
indirectly through co-morbidities. Electrocardiograms are recom-
mended for older or persistent methadone clients on higher doses
(Medicines and Healthcare products Regulatory Agency (MHRA),
2006) to detect QTc prolongation (see Discussion section, below),
for which being female (Makkar et al., 1993; Kest et al., 2000; Lee
and Ho, 2013; Graziani and Nistico, 2015; Bawor et al., 2014), co-
morbidities and co-prescribing are also risk factors.
As access to OST has expanded, the opioid-specificity of DRDs in
Scotland, as elsewhere, has changed (Strang et al., 2010; Zador and
Sunjic, 2002; Seymour et al., 2003; McCowan et al., 2009; Bird and
Robertson, 2011; Pilgrim et al., 2013; Bernard et al., 2013; Cousins
et al., 2016; Winker et al., 2014; Kimber et al., 2015). National
Records of Scotland (NRS, 2015) now publishes, as official statis-
tics, Scotland’s number of opioid-related deaths cross-tabulated by
gender and age-group. Co-presence of benzodiazepines or  alcohol
at DRDs has been remarked upon (Seymour et al., 2003; McCowan
et  al., 2009; Bird and Robertson, 2011; Christie, 2011; Leece et al.,
2015; Park et al., 2015) but, whereas diazepam was  present at 70%
of Scotland’s DRDs in 2013 or 2014, diazepam was implicated in
only 14% of Scotland’s DRDs; and, when present, was prescribed in
the past 30 days for only one in  six DRDs (Barnsdale et al., 2015,
2016) and so was mainly illicitly acquired.
1 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
The recent rise in Scotland’s methadone-implicated DRDs, and
likewise in England (White and Hamilton, 2016), re-ignited concern
about long-term treatment with methadone or its possible diver-
sion. Scotland’s National Drugs-Related Death Database (Barnsdale
et al., 2015)  reported that methadone was  not  prescribed at the
time of death in 2013 for 41% of those in whose DRD methadone
was implicated. Too low a  daily-dose of methadone, of  course, com-
promises retention in OST (Kimber et al., 2010) and, since being
off-OST doubles clients’ DRD-risk, the public health challenge in
2016, as in 1999 (Ward et al., 1999), is  to  deliver safe and effective
forms of OST for as long and to  as many ageing opioid-dependent
individuals as can benefit (Department of Health et al., 2007).
Hence, in  this paper, our aims were:
1 To document DRD-rates and methadone-specific DRD  rates by
gender and age-group for Scotland’s cohort of CHI-identified
methadone clients between July 2009 and June 2013;
2 To apply proportional hazards regression to  analyse risk factors at
cohort-accrual (including quintile for the quantity of prescribed
methadone) for methadone-specific DRDs; and for all DRDs.
2. Methods
2.1. Drug related deaths
We used the UK harmonized definition of DRD (National Records
of Scotland, 2015) and requested information on the opioid-
specificity of Scotland’s DRDs from NRS as follows:
i) Methadone-specific DRDs: methadone was implicated in  DRD,
but neither heroin nor buprenorphine was implicated,
ii) Heroin-specific DRDs: heroin was  implicated in  DRD, but nei-
ther methadone nor buprenorphine was implicated,
iii) DRDs in  which methadone and heroin were both implicated,
but buprenorphine was not.
In appraising which drugs are implicated as causal factors in
any DRD and which, although present, probably did not contribute,
Scotland’s pathologists are supported by having a national protocol
for toxicological testing at forensic autopsies.
2.2. Scotland’s community health index and CHI-number
The CHI is a  register of all patients in  Scotland’s publicly funded
healthcare system, NHS Scotland. Patients are  identified by a  10-
digit CHI-number, usually the patient’s date of birth (DDMMYY)
followed by four digits: two  randomly generated, the third identi-
fying gender (odd for males) and the fourth a  check digit (see Pavis
and Morris (2015) on the criticality of CHI-numbers for Scotland’s
efficient, trusted record-linkage).
2.3. Record-linkage for Scotland’s methadone-client cohort
To assess explanatory factors for methadone-specific DRDs
among those who  had been prescribed methadone in Scotland in
2009–2013, we needed to link methadone-prescriptions to NRS’s
mortality records. Because all deaths are CHI-identified, Scot-
land’s CHI-number was used for this exact record-linkage. We
defined Scotland’s methadone-prescription cohort as: clients who
had received one or more CHI-identified methadone prescriptions
(from GP  or other-source) during 1 July, 2009–30 June 2013. In
the Results section, below, we report the percentage of  methadone
prescriptions that were CHI-identified (63%) and the higher esti-
mated percentage of methadone clients (82%) with at least one
CHI-identified prescription.
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The cohort was followed-up for mortality until 31 December
2013. Time at risk began at the date of the client’s first CHI-
identified prescription during 1 July, 2009–30 June 2013 and ended
at the earlier of death-date or 31 December 2013. The research-file
was prepared in October 2014. As the requested date of the first
CHI-identified prescription was missing for 61%  of clients, the date
of its re-imbursement was substituted. When both dates were pro-
vided, the re-imbursement date was, on average, 37 days later (sd
19 days).
Unlike in England and Wales, death registrations in  Scotland
occur within eight days of death having been ascertained (Bird,
2013, 2016); and NRS publishes official statistics on  DRDs that
occurred in year y in  mid-August of the following year (y + 1).
Our record-linkage protocol was approved by Scotland’s Pri-
vacy Access Committee. To preserve client confidentiality, all
CHI-identified methadone-prescriptions and death-records were
pseudonymized in a  manner which enabled the research team
to link CHI-identified prescriptions and death-information for the
same client.
2.4. Methadone-prescriptions
Methadone-prescriptions were accessed from Scotland’s Pre-
scribing Information System (Alvarez-Madrazo et al., 2016)  which
contains information on all prescriptions written in Scotland and
dispensed in the community. Only CHI-identified methadone-
prescriptions for the same individual were linkable. The CHI-rate
for methadone-prescriptions differed by year (higher in  2012/13
than in 2009/10) and prescription-source (higher for GPs than
other-source prescriptions; see Dimitropoulou et al., 2016).
The quantity of methadone prescribed was always available as
pharmacies are re-imbursed for the quantity prescribed. Duration
of methadone-prescription and daily-dose could only be derived
for GP prescriptions which had used an electronic dose instruc-
tion message. Natural language programming was  applied to the
free-text of this electronic message to abstract daily-dose (see
Dimitropoulou et al. (2016) for the programme details). Extraction-
rates for daily-dose of prescribed methadone were 79.3% from
140,361 electronic dose instruction GP-prescriptions in  2009/10
and 94.4% for 133,386 GP-prescriptions in 2012/13 (Dimitropoulou
et al., 2016).
2.5. Statistical methods
Time at risk in days was converted to  person-years (pys) by
dividing the number of days at risk by  365.25 days. If prescription-
date was missing, the later re-imbursement date was substituted
(see above), which accounted for some negative time-intervals
from the first CHI-identified prescription-date to death-date. With-
out loss of generality, we added 60 days to all times at risk and so
fitted proportional hazards regression models to the time-at-risk
plus 60 days, which avoided almost all negative times as the 90th
percentile for the known re-imbursement delays was  60 days.
Only baseline covariates (that is: not time-varying, see below
for reasons) were assessed, namely: those defined by the client’s
first CHI-identified methadone-prescription between July 2009 and
June 2013. Baseline covariates were prescription-source (GP vs.
other-source); gender, age-group and their interaction; quintiles
for the quantity of methadone prescribed; plus regions with his-
torically high prevalence of heroin injecting (Greater Glasgow and
Clyde, Lothian, Tayside, versus rest of Scotland) as a  potential con-
founder.
Our reasons for not updating the quantity of methadone pre-
scribed were three-fold: death informatively censors subsequent
methadone-prescriptions; follow-up continued for six-months
beyond the four years for accrual of CHI-identified methadone-
prescriptions; and a client’s later methadone-prescriptions, even
within the four years, need not be  CHI-identified. Hence, the date
of a  client’s last CHI-identified methadone-prescription prior to 30
June 2013 does not  necessarily indicate the date when methadone-
prescribing ceased. By investigating accrual covariates only, which
all clients have by definition, we introduced neither informative
censoring nor ascertainment bias.
We  investigated influential baseline covariates for methadone-
specific DRDs, our  focal interest; and for all  DRDs, as the
conventional analysis. As a sensitivity check, we analysed
methadone-specific DRDs separately for clients accrued in 2009
(mostly prevalent) versus later  (mostly incident).
For  the subset of GP-clients for whom daily-dose of methadone
at the first CHI-identified prescription was known, we also investi-
gated quintiles for daily-dose of prescribed methadone.
We used STATA 12.1 for analysis. We  present 95% confidence
intervals for deaths per 1000 pys; and for hazard ratios (HRs).
3. Results
During 2009/10 to 2012/13, Scotland had 2,030,457 methadone
prescriptions, 1,282,555 (63%) of which were CHI-identified. The
CHI-identified prescriptions related to 33,128 methadone clients,
82% of Scotland’s 40,606 methadone clients during 2009/10 to
2012/13, as best-estimated using the method of Dimitropoulou
et al. (2016).
The majority (63%, 20,758 clients) joined the cohort in  July
to  December 2009, mostly prevalent clients. During follow-up of
121 254 pys to  31 December 2013, there were 1931 deaths. The
cohort experienced 1171 non-DRDs and 760 DRDs at rates of 9.7
non-DRDs (95% CI: 9.1–10.2) and 6.3 DRDs (95% CIs:  5.8–6.7) per
1000 pys respectively. Buprenorphine was implicated in  only seven
DRDs and there were 67 DRDs in which none of heroin/morphine,
methadone, or buprenorphine was implicated.
3.1. Demographic and other risk-factors
Methadone-specific DRDs (362) were more than double the
cohort’s number of heroin-specific DRDs (173) or DRDs in which
both heroin and methadone but not buprenorphine were impli-
cated (151), see Table 1.
Opioid-specificity of clients’ DRDs varied by prescription-
source, gender and age-group at cohort-entry. [The non-DRD:
DRD ratio also varied by covariates, for example: higher for GP-
prescribers and older clients.]
Clients whose first CHI-identified methadone-prescription was
other-source had a higher methadone-specific DRD-rate. By gen-
der, the male heroin-specific DRD-rate was significantly higher at
1.8 per 1,000 pys (5% CI: 1.4–2.0) than for females (0.8, 95% CI:
0.5–1.1) but clients’ methadone-specific DRD-rate was 3.0 irrespec-
tive  of gender.
Clients whose age at first CHI-identified prescription in
2009–2013 was  35+ years had a DRD-rate of 7.7 (95% CI: 7.0–8.4)
versus 4.9 (95% CI: 4.4–5.5) per 1,000 pys for younger clients. In par-
ticular, methadone-specific DRD-rates were substantially higher in
the older age-group than for younger clients: 4.2 (95% CI: 3.6–4.7)
versus 1.9 (95% CI: 1.5–2.2) per 1,000 pys.
For older clients, neither the DRD-rate nor the methadone-
specific DRD-rate was  lower for females. By contrast, in  the younger
age-group, the DRD-rate was  higher for males than females, see
Table 1: interaction.
Regional variation in the methadone-specific DRD-rates was
unremarkable (chi-square on 3df of 5.78, p = 0.12). However, Tay-
side’s significantly high DRD-rate could be a  confounder when
analysing DRDs.
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Table  1
For major sub-groups, numbers of deaths by  defined opioid-specificity and person-years (pys) at  risk since first CHI-identified prescription to  earlier of death-date or 31
December 2013.
Sub-group defined by 1st
CHI-identified prescription
Clients Non-DRDs DRDs Opioid-specific DRD sub-groups Person-years, pys
Heroin: yes Heroin: no Heroin: yes
Meth: no Meth: yes Meth: yes
Bupren: no Bupren: no Bupren: no
Scotland-wide 33 128 1171 760 173 362 151 121 254  pys
Death-rate per 9.7 6.3 1.4 3.0 1.2
1000 pys (95% CI) (9.1–10.2) (5.8–6.7) (1.2–1.6) (2.7–3.3) (1.0–1.4)
Prescription source
GP-prescription 22 114 887 502 130 232 86  84 338 pys
Death-rate per 10.5 6.0 1.5 2.8 1.0
1000 pys (95% CI) (9.8–11.2) (5.4–6.5) (1.3–1.8) (2.4–3.1) (0.8–1.2)
Other-source 11 014 284 258 43  130 65  36 916 pys
Death-rate per 7.7 7.0 1.2 3.5 1.8
1000 pys (95% CI) (6.8–8.6) (6.1–7.8) (0.8–1.5) (2.9–4.1) (1.3–2.2)
Gender
Males  22 025 827 535 141 240 108 80 394 pys
Death-rate per 10.3 6.7 1.8 3.0 1.3
1000 pys (95% CI) (9.6–11.0) (6.1–7.2) (1.4–2.0) (2.6–3.4) (1.1–1.6)
Females 11 103 344 225 32  122 43  40 860 pys
Death-rate per 8.4 5.5 0.8 3.0 1.1
1000 pys (95% CI) (7.5–9.3) (4.8–6.2) (0.5–1.1) (2.4–3.5) (2.4–3.5)
Age-group at Cohort-Entry
35+  years @ Cohort-entry 16 002 886 451 78  244 86  58 462 pys
Death-rate per 15.2 7.7 1.3 4.2 1.5
1000 pys (95% CI) (14.2–16.2) (7.0–8.4) (1.0–1.6) (3.6–4.7) (1.2–1.8)
<  35 years @ Cohort-entry 17 126 285 309 95  118 65  62 792 pys
Death-rate per 4.5 4.9 1.5 1.9 1.0
1000 pys (95% CI) (4.0–5.1) (4.4–5.5) (1.2–1.8) (1.5–2.2) (0.8–1.3)
Gender by Age-group at Cohort-Entry: interaction
Male,  35+ 11 540 632 320 68  163 63  42 126 pys
Death-rate per 15.0 7.6 1.6 3.9 1.5
1000 pys (95% CI) (13.8–16.2) (6.8–8.4) (1.2–2.0) (3.3–4.5) (1.1–1.9)
Female, 35+ 4  462 254 131 10 81 23  16 336 pys
Death-rate per 15.5 8.0 0.6 5.0 1.4
1000 pys (95% CI) (13.6–17.5) (6.6–9.4) (0.3–1.1) (3.9–6.0) (0.9–2.1)
Male,  < 35 10 485 195 215 73  77 45  38 268 pys
Death-rate per 5.1 5.6 1.9 2.0 1.0
1000 pys (95% CI) (4.4–5.8) (4.8–6.4) (1.5–2.4) (1.5–2.5) (0.8–1.5)
Female, < 35 6  641 90 94 22  41 20 24 524 pys
Death-rate per 3.7 3.8 0.9 1.7 0.8
1000 pys (95% CI) (2.9–4.4) (3.1–4.6) (0.5–1.4) (1.1–2.2) (0.5–1.3)
Region at cohort entry
G. Glasgow & Clyde 12 261 525 307 82  135 56  47 465 pys
Death-rate per 11.1 6.5 1.7 2.8 1.2
1000 pys (95% CI) (10.2–12.0) (5.8–7.2) (1.4–2.1) (2.6–4.3) (0.9–1.5)
Lothian 4  801 170 84 10 58 11  17 423 pys
Death-rate per 9.8 4.8 0.6 3.3 0.6
1000 pys (95% CI) (8.4–11.3) (3.9–6.0) (0.3–1.1) (2.5–4.2) (0.4–1.1)
Tayside 2  760 87 74 7  34 23  8 034 pys
Death-rate per 10.8 9.2 0.9 4.2 2.9
1000 pys (95% CI) (8.8–13.4) (7.3–11.6) (0.4–1.8) (3.0–5.9) (1.9–4.3)
Rest  of Scotland 13 306 389 295 74  135 61  48 335 pys
Death-rate per 8.0 6.1 1.5 2.8 1.3
1000 pys (95% CI) (7.2–8.8) (5.4–6.8) (1.2–1.9) (2.4–3.3) (1.0–1.6)
3.2. Proportional hazards analyses
Only four time-intervals remained negative after the universal
addition of 60 days (see Methods section) and so, without loss of
generality, these few clients were excluded from regression analy-
ses. Two were DRDs, one of them methadone-specific.
Quintiles for the quantity of methadone prescribed at first
CHI-identified prescription were as follows: <  =  280; 281–700;
701–1200; 1201–1960; and >1960 mg.  As shown in  Supplementary
material2, quintiles for daily dose of prescribed methadone in the
2 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
GP-subset with e-readable dose instructions were: <  =  30; 31–50;
51–70; 71–90; and >90 mg.
With neither region nor gender by age-group interaction fitted
and irrespective of whether quintiles were fitted, clients’ age-
related HRs were steeper for methadone-specific DRDs (Table 2,
top panel) than for all DRDs (Table 3, top panel): for example, HRs
of 1.9 and 2.9 for the two oldest age-group in Table 2  versus 1.4
and 1.9 in Table 3.  The highest quintile for quantity of prescribed
methadone was associated with a  HR for 1.8 (95% CI: 1.3–2.5) for
methadone-specific DRDs but not for all DRDs.
The lower panel of Table 3 confirmed the familiar gender by age-
group interaction for DRD-hazards, and showed that confounding
by region was largely responsible for the apparently higher DRD-
hazard in  Table 1 for other-source prescriptions.
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Table  2
Proportional hazards analysis from first  CHI-identified prescription to methadone-specific DRDs: with adjustment for baseline covariates excluding or including quintiles
for  prescribed quantity of methadone.
Covariates
361 Methadone-specific DRDs; 33,124 at-risk clients
Regression chi-square test on  3df for interaction (gender*age-group)
when region also fitted = 3.30, p  ∼0.35
Excluding QUINTILES for
prescribed quantity
Including QUINTILES for
prescribed quantity
Regression chi-square (9 df) =  98.88
HR 95% CI p-value HR 95% CI p-value
No interaction needed for gender *  age-group
Regression chi-square (4df) for QUINTILES 22.98, p ∼0.0001
Other-source 1.42 1.15–1.77 0.001 1.44 1.16–1.79 0.001
Female  1.12 0.90–−1.39 0.322 1.14 0.91–1.42 0.246
AGE-GROUP with 25–34 years at  first CHI-identified prescription as baseline
Age < 25 0.51 0.26–1.00 0.050 0.53 0.27–1.04 0.064
Age  35–44 1.95 1.53–2.48 <0.001 1.91 1.50–2.44 <0.001
Aged  45+ 2.95 2.18–4.00 <0.001 2.90 2.14–3.93 <0.001
QUINTILES for prescribed quantity of methadone with lowest quintile as baseline
Quintile 2: 281–700 1.10 0.76–1.59 0.604
Quintile 3: 701–1200 0.90 0.61–1.32 0.577
Quintile 4: 1201–1960 1.22 0.86–1.74 0.261
Quintile 5: > 1960 mg(For example, 1960 mg = 14 days@140 mg daily or28 days @ 70 mg) 1.79 1.29–2.50 <0.001
When covariates for  REGION [Greater Glasgow and Clyde (as baseline) versus Lothian, Tayside, rest of Scotland] were added to the above models, neither
regression chi-square (on 3df) for REGION was statistically significant, see below.
Regression chi-square (3df) for REGION 5.80, p ∼0.12 2.42, p  ∼0.49
There was no female advantage when it came to methadone-
specific DRDs, nor regional differences (unlike for all DRDs). For
clients whose first CHI-identified prescription was  other-source,
the HR for methadone-specific DRDs was 1.4 (95% CI: 1.2–1.8).
For mostly prevalent clients (those recruited in July to  December
2009), the quantity of prescribed methadone at cohort-entry was
likely to represent the clients’ typical or stabilized prescription
but, for mostly incident clients (those recruited after 2009, for 34%
of whom the quantity of prescribed methadone was  in  the low-
est quintile), quantity prescribed at cohort-entry was  more likely
to represent initial prescribing. See Supplementary material3 for
pH analysis of methadone-specific DRDs separately for clients who
accrued in July to December 2009 (mostly prevalent) versus later.
The  stratification was highly significant (chi-square test on 9 df of
28.21, p ∼0.0009) with four main points of difference. Other-source
prescribing applied for half the mostly incident clients (versus
only 22% of 2009-accrued clients) and, for them, was  associated
with a significantly greater hazard of methadone-specific DRD (test
for  interaction: p ∼0.05). For clients aged 45+  years, the HR for
methadone-specific DRD was more extreme for mostly incident
than mostly prevalent clients. Thirdly, clients who entered the
cohort after 2009 with a baseline quantity of prescribed methadone
of 281–700 mg were at relatively greater risk of methadone-specific
DRD than their mainly prevalent counterparts. Fourth, the highest
quintile for quantity of prescribed methadone applied to only 13%
of mostly incident clients but was associated with a notably high
HR of 2.8 (95% CI: 1.5–5.1) for methadone-specific DRD.
For the GP-subset of clients with known daily-dose at their first
CHI-identified prescription, the highest quintile for daily-dose of
prescribed methadone (>90 mg)  may  be even more prognostic than
for quantity prescribed, see Supplementary material4
3 Supplementary material can be found by  accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
4 Supplementary material can be found by  accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
4. Discussion
4.1. Summary of main findings
Scotland’s methadone-prescription cohort reveals for the first
time that clients’ age-related hazard increases more steeply for
methadone-specific DRDs than for all DRDs (e.g.,HR for males aged
45+ years: 2.9 versus 1.9). Although Pierce et al. (2015a, 2016)
showed that DRD-rates increased beyond 45 years of age for Eng-
land’s drug treatment clients, they did not have information on
the opioid-specificity of DRDs to  enable an analysis of methadone-
specific DRDs. Nor did they have information on the quantity of
prescribed methadone. Importantly, the steeply age-related HRs
for methadone-specific DRDs in Scotland’s methadone client cohort
were evident in Table 2, even without fitting quintiles for the quan-
tity of methadone and so validation studies in  other OST cohorts,
which are necessary, can proceed primarily by ascertaining the
opioid-specificity of their DRDs.
Unlike for all DRDs, there was no overall hazard-reduction for
females in respect of methadone-specific DRDs; no gender by  age-
group interaction, see Table 1; and consistent with the Scottish
Drug Strategy Delivery Commission’s endorsement of  the pro-
fessional standards by which OST was delivered in  Scotland, no
regional variation. For methadone-specific DRDs, but not all DRDs,
the highest quintile for quantity of prescribed methadone was asso-
ciated with significantly increased hazard (1.8; 95% CI:  1.3–2.5).
4.2. Key considerations
Unlike buprenorphine, methadone −  alone and with other
drugs commonly used for mental health conditions (see Medicines
and Healthcare products Regulatoy Agency (MHRA), 2006) and
NHS Greater Glasgow and Clyde Medicines Information Service,
2012)—is  known to affect the electrical conductivity of  the heart
muscle. Specifically, prolongation of part of the normal electrical
cycle, known as the QT interval, and measurable by an electro-
cardiogram (ECG), can occur (Wedman et al., 2007; Kornick et al.,
2003; Peles et al., 2007; Weimer and Chou, 2014; Chou et al.,
2014a, 2014b; Bohnert et al., 2001; Gomes et al., 2011; Liang and
Yurner, 2015). Prolongation of the corrected QT interval (cQT) and
its sequelae of torsades de pointes has been associated with the
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risk of sudden cardiac death (Maremmani et al., 2005; Roden,
2006; Justo et al., 2006; Fanoe et al., 2007; Chugh et al., 2008).
Whether undiagnosed QTc prolongation contributes to the tally
of methadone-specific DRDs is  unknowable because prolongation
leaves no detectable trace at autopsy (Chugh et al., 2008). Other risk
factors for QTc prolongation include co-morbidities such as renal
impairment, heart or  liver disease; and being female (Makkar et al.,
1993; Kest et al., 2000; Lee and Ho, 2013; Graziani and Nistico,
2015; Bawor et al., 2014).
In 2006, MHRA recommended that any patient requiring more
than 100 mg  of methadone per day should be closely monitored.
Periodic heart monitoring of methadone clients has been recom-
mended to detect QTc prolongation by 60 milliseconds or to above
500 milliseconds, but evidence on the effectiveness of such screen-
ing is weak (Pani et al., 2013): with detection in  perhaps 2% of
clients and mostly on doses greater than 100 mg daily. The quan-
tity of prescribed methadone was >1960 mg for a  fifth of Scotland’s
methadone-prescription clients (and >90 mg daily for 18% of the
GP subset) and so we speculate that the ECG-detection rate for QTc
prolongation could between 5% and 10% for Scotland’s methadone-
prescription clients in the top quintile of prescribed methadone.
Moreover, ECGs on a  representative sample of only 200 clients from
the top quintile, if they were willing to  attend for screening, could
estimate the detection-rate for QTc prolongation rather well: with
a  standard error of about 2%. However, the clear HR warning in
Table 2 is that precautionary monitoring, including by ECG, may  be
warranted for all methadone clients over 45 years of age.
Table 3
Proportional hazards analysis from first CHI-identified prescription to  DRD: with adjustment for baseline covariates excluding or including quintiles for prescribed quantity
of  methadone.
Covar iates
(nu mber of cli ents )
758  Drug-Related Deaths; 33 ,124  at-risk cli ents
Exclud ing QUINTILES for 
prescribed qu anty
Includ ing QUINTILES for 
prescribed qu anty
HR 95% CI p-value HR 95% CI p-value
No interacon
Regression chi-squar e (4df)  for  QUINTILES 19.95 , p ~ 0.0005
Other-source 1.27 1.09-1.48 0.002 1.30 1.12-1.52 0.001
Female 0.88 0.75-1.03 0.118 0.88 0.75-1.03 0.12 3
AGE-GROUP with 25-34 years at ﬁrst CHI-idenﬁed prescripon as baseline
Age < 25 ( 2 50 9) 0.70 0.48-1.02 0.062 0.69 0.47-1.00 0.05 3
Age 35-44 (12 377) 1.40 1.20-1.65 <0.001 1.42 1.20-1.66 <0.001
Aged 45+ ( 3 62 2) 1.90 1.53-2.36 <0.00 1 1.91 1.54-2.38 <0.00 1
QUINTILES for prescribed quanty of methadone with lowest quinle as baseline
Quinle 2:   281- 700 1.14 0.91-1.42 0.255
Quinle 3:   701- 1200 0.74 0.58-0.95 0.017
Quinle 4: 120 1- 196 0 0.86 0.68-1.09 0.206
Quinle 5: > 1960mg
(For example, 196 0mg =
14 days@140mg daily or 
28 day s @ 70 mg)
1.02 0.82-1.28 0.841
Includ ing REGION and  Interacon for gender * age-group
Regression chi-squar e (4df)  for  QUINTILES 17.18 , p ~ 0.00 18
Other-source 1.15 0.96-1.38 0.12 8 1.17 0.97-1.41 0.09 1
Female 0.74 0.57-0.96 0.02 2 0.74 0.57-0.96 0.02 3
AGE-GR OUP with 25-34  years at ﬁrs t CHI-idenﬁed prescripon as  bas eli ne
Age < 25 0.92 0.58-1.46 0.726 0.91 0.57-1.44 0.67 6
Age 35-44 1.27 1.05-1.53 0.01 5 1.28 1.06-1.55 0.01 2
Aged 45 + 1.67 1.29-2.16 <0.00 1 1.68 1.29-2.17 <0.00 1
Female age <25 (1 35 9) 0.53 0.24-1.18 0.121 0.54 0.24-1.19 0.12 6
Female, 35-44 (3 438) 1.39 0.98-1.97 0.064 1.39 0.98-1.97 0.065
Female age 45+ (1 024) 1.53 0.96-2.44 0.077 1.52 0.95-2.43 0.078
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Table 3 (Continued)
QUINTILES for prescri bed qu anty of methad one with lowest qu inle as baseline
Quinle 2:   281- 700 1.15 0.92-1.43 0.23 1
Quinle 3:   701- 1200 0.74 0.58-0.95 0.01 9
Quinle 4: 120 1- 196 0 0.85 0.67-1.07 0.16 3
Quinle 5: > 1960  mg
(For example, 196 0mg =
14 days@14 0mg daily or  
28 day s @ 70 mg) 
1.05 0.84-1.32 0.68 2
REGION with Gr eater Glas gow & Cl yde as  bas eli ne
Lothian 0.79 0.62-1.00 0.05 5 0.77 0.60-0.98 0.03 7
Tayside 1.47 1.09-1.96 0.01 0 1.49 1.11-2.00 0.00 8
Rest of Scotland 0.97 0.81-1.16 0.73 6 0.97 0.82-1.16 0.78 0
Regression  chi-squar e 
(3df)  for  REGION
13.11 , p ~ 0.00 44 14.51 , p ~ 0.00 23
In view of the above risk-factors for QTc prolongation, future
record-linkage for Scotland’s CHI-identified methadone clients will
seek to link-in not only clients’ diagnoses for blood-borne viruses
(Hepatitis B, C and HIV) but also cardiac, gastro-intestinal, alcohol-
related (Hutchinson et al., 2005; McDonald et al., 2008, 2010) and
mental-health hospitalizations to try to  unravel contributory fac-
tors to methadone-specific DRDs’ strong age-gradient and absent
gender effect. Co-prescription of benzodiazepines is  likely to be
of little help, however, as illicit  access predominates at DRDs
(Barnsdale et al., 2015, 2016). Self-reported misuse of benzodi-
azepines has, however, been shown to  increase DRD-risk (Pierce
et al., 2016).
The quantity of methadone prescribed at cohort-entry was
available for all clients. Quantity prescribed played a  key role
in clients’ risk of methadone-specific DRD, but not for all DRDs.
For the GP subset, daily-dose of prescribed methadone (>90 mg)
underlined the association. Despite inevitable uncertainties about
causation (Hill, 1965), the novel findings from Scotland—a first
and so requiring external corroboration—serve to emphasise 21st
century alerts to prescribers and their opioid-dependent clients,
especially new clients, to  be cautious if  either the quantity of
methadone prescribed exceeds 1,960 mg (for example: 140 mg for
14 days; or, typically, over 90 mg  daily for 28 days but dispensed
in 21 instalments, see Supplementary material5); or daily-dose
exceeds 90 mg.  Similar warnings about daily-dose in  excess of
100 mg have been enunciated for patients receiving methadone
for non-cancer pain (Chou et al., 2014a, 2014b) who, for the most
part, would not have progressive liver disease (Gibson et al., 2011;
Pierce et al., 2015a) or other co-morbidities. Co-morbidities clearly
affect Scotland’s ageing methadone clients (Hutchinson et al., 2005;
McDonald et al., 2008, 2010; Kimber et al., 2010; Merrall et al.,
2012). The Scottish data suggests that prescribers may  need to dis-
cuss risk-mitigation with all methadone clients over 45 years of
age.
We found an increased adjusted hazard of methadone-specific
DRD for other-source prescribers, more particularly for incident
clients. A contributory factor here could be that the physical and
5 Supplementary material can be found by  accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
psychiatric history, and hence frailty of these clients, is less well-
known to other-source prescribers than by GPs.
4.3. Strengths and limitations of this study
First, Scotland has a national protocol for toxicological testing
at forensic autopsy which underpins the opioid-specificity of its
DRDs. Secondly, unparalleled for a  national cohort (Sullivan et al.,
2014), we could analyse the quantity of methadone prescribed at
cohort-entry in  addition to  demographic risks for a large cohort of
33,000 methadone-clients who  experienced 760 recent-past DRDs,
362 of them methadone-specific DRDs.
Third, to minimize ascertainment bias, we considered only the
baseline (not time-varying) quantity of methadone prescribed at
the first CHI-identified methadone prescription. This first CHI-
identified prescription defined the client’s entry to  Scotland’s
methadone-client cohort (2009–2013) but was  typically not the
client’s first methadone prescription, especially if cohort-entry
was in 2009. We  therefore investigated covariate influences on
methadone-specific DRDs separately for mostly prevalent clients
versus those accrued after 2009 whose baseline quantity of  pre-
scribed methadone may  have been pre-stabilization. Besides a
differential association with other-source prescribing, we  found
that two other hazards for methadone-specific DRD were more
extreme for the mostly incident than for mostly prevalent clients:
aged 45+ years and highest quintile for quantity prescribed. Both
underscore our  main findings.
Turning to limitations, of which there are several, we  acknowl-
edge first that  only 63% of all methadone prescriptions during
2009/10 to 2012/13 were CHI-identified. However, our  33,128 CHI-
identified methadone clients represented, at a best estimate, 82% of
Scotland’s methadone-clients over the four years (plausible range:
70% to 93%), a more critical measure of completeness being client-
based.
The unavailability of daily-dose for other-source prescriptions
and for half of the first CHI-identified prescriptions by  GPs is, of
course, regrettable: and especially so as our analysis in  Supplemen-
tary material6 for the GP-subset suggested that the highest quintile
6 Supplementary material can be found by  accessing the online version of this
paper at http://dx.doi.org and by  entering doi:. . .
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for daily prescribed methadone was more prognostic even than
the quantity prescribed. Irrespective of whether daily-dose was
available or not, summary statistics on the number of prescription-
instalments by GPs were reassuringly similar so that any bias in
the GP-subset may  be more apparent than real. Nonetheless, we’d
have preferred that  daily-dose at first CHI-identified prescription
had been accessible electronically for 80% or more clients.
The need to substitute, for missing first prescription-date, the
later reimbursement-date was a  minor issue. More importantly,
we did not know, and hence could not analyse (Cornish et al.,
2010; Pierce et al., 2015a; Cousins et al., 2016), when clients exited
from methadone therapy as the date of their last CHI-identified
methadone-prescription does not exclude later non-CHI prescrip-
tions. Hence, once included in the cohort, clients have remained in
follow-up.
A fifth limitation, in  common with most unconsented record-
linkage studies, is  that we had little scope for resolving
data-queries, such as some apparent inconsistencies (2%) between
quantity of methadone prescribed and daily-dose.
Benzodiazepines (licit or illicit), alcohol and methadone con-
spire in terms of DRD-risk (Merrall et al., 2012; Pierce et al., 2015a,
2016), as evidenced by  their co-presence at DRDs (Bird et al.,
2010; Bird and Robertson, 2011; Barnsdale et al., 2015, 2016)
and by the co-prescription of benzodiazepines with opioids for
pain (Christie, 2011; Leece et al., 2015; Park et al., 2015). We  did
not request that methadone clients’ co-prescriptions for benzo-
diazepines be linked-in because the added time and complexity
would not have been warranted given that illicit supplies would
remain unaccounted for and, among Scotland’s DRDs, are the sub-
stantial majority (Barnsdale et al., 2015, 2016).
Seventh, association is  not causation (Hill, 1965): age over
45 years and higher quantity of methadone prescribed may
be  respectively demographic and pharmacological markers for
harder-to-support clients whose opioid dependency is chronic and
likewise their HCV progression (Eap et al., 2002). Research into
gender differences in  opioid analgesia and addiction has given con-
flicting results (Lee and Ho, 2013; Graziani and Nistico, 2015; Bawor
et al., 2014) but being female is a  risk-factor for QTc prolongation
(Makkar et al., 1993), which may  partly explain why, for females,
the risk of methadone-specific DRDs is not lower than for their male
counterparts.
5. Conclusions
Vindicating our hypothesis, Scotland’s methadone-prescription
cohort has revealed high methadone-specific DRD rates in  older
clients irrespective of gender; and increased hazard for the
top quintile of prescribed methadone. Better understanding is
needed of the pharmaco-dynamics of methadone for older, opioid-
dependent clients, many with progressive liver, cardiovascular or
other disease.
Guidelines on the prescribing of methadone in the UK will
be updated in 2016. The Scottish data signal that methadone-
prescribers and other specialists should exercise particular caution
in managing older clients, many of whom are HCV-infected or
alcohol-dependent; and if their daily-dose of methadone exceeds
90 mg  or the quantity of methadone per prescription exceeds
1960 mg.
Higher methadone-specific DRD-rate for older clients, and the
absence of a gender differential, should be noted by prescribers and
by clients themselves. We  recommend that take-home naloxone
be prescribed for methadone-clients (Strang et al., 2014; Bird et al.,
2015, 2016),  especially those aged 35+ years.
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